Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. März 2013 07:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results

CAMBRIDGE, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
28. Februar 2013 08:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Observes Rare Disease Day

CAMBRIDGE, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
07. Januar 2013 07:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID(TM) (lomitapide) Capsules

CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
24. Dezember 2012 07:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

FDA Approves Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...
13. Juni 2012 08:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Participation at Wells Fargo Securities 2012 Healthcare Conference

CAMBRIDGE, Mass., June 13, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
30. Mai 2012 08:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Participation at Jefferies 2012 Global Healthcare Conference

CAMBRIDGE, Mass., May 30, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
29. Mai 2012 08:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Oral Presentation of Phase III Lomitapide Data at European Atherosclerosis Society Conference

CAMBRIDGE, Mass., May 29, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
01. Mai 2012 07:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces First Quarter 2012 Financial Results

CAMBRIDGE, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
30. April 2012 08:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces FDA Acceptance of New Drug Application for Review

CAMBRIDGE, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
20. März 2012 07:00 ET | Quelle: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces EMA Acceptance for Review of Marketing Authorization Application for Lomitapide

CAMBRIDGE, Mass., March 20, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...

Nächste Seite